Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study Of Bevacizumab (rhuMAb VEGF) In Combination With OSI-774 For Patients With Recurrent Or Metastatic Cancer Of The Head And Neck

NCT00055913 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00055913
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00055913 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study Of Bevacizumab (rhuMAb VEGF) In Combination With OSI-774 For Patients With Recurrent Or Metastatic Cancer Of The Head And Neck
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2003
Completion date
Not reported
Enrollment
58 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent squamous cell carcinoma of the hypopharynx, recurrent squamous cell carcinoma of the larynx, recurrent squamous cell carcinoma of the lip and oral cavity, recurrent squamous cell carcinoma of the nasopharynx, recurrent squamous cell carcinoma of the oropharynx, recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity, salivary gland squamous cell carcinoma, stage iv squamous cell carcinoma of the hypopharynx, stage iv squamous cell carcinoma of the larynx, stage iv squamous cell carcinoma of the lip and oral cavity, stage iv squamous cell carcinoma of the nasopharynx, stage iv squamous cell carcinoma of the oropharynx, stage iv squamous cell carcinoma of the paranasal sinus and nasal cavity